Fractyl Health, Inc.
Moat Score — Fractyl Health, Inc.
Total Moat Score
5 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 2 / 5 | Fractyl holds patents and trade secrets around its duodenal ablation (Revita) and AAV gene-delivery (Rejuva) technology, plus Breakthrough Device designations and CE marking, but it acknowledges its own patent protection may be insufficient against well-funded competitors. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 0 / 5 | As a pre-revenue, pre-commercial company funding two clinical pipelines, Fractyl has no cost advantage of any kind; it is a cash-burning R&D operation, not a low-cost producer. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 1 / 5 | With no approved product, Fractyl has no demonstrated pricing power yet; its roughly $10,000 per-year ICER benchmark for Rejuva is an aspirational payer target, not evidence of real market pricing leverage. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | Fractyl's business has no network effect — value to one patient or physician does not increase as more patients or physicians adopt Revita or Rejuva. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 1 / 5 | If approved, Revita could become embedded in a physician's existing endoscopy workflow via the hub-and-spoke rollout, but today there is no installed base or switching cost to speak of since nothing is commercially deployed. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 1 / 5 | The metabolic disease and obesity-rebound market Fractyl targets is enormous rather than naturally scale-limited, so efficient scale is not a meaningful moat source here; if anything the market's size invites more entrants, not fewer. |